# NCT05706129 (NCT05706129)

> A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors

No report yet. It can be ordered.

- Drugs tested: [177Lu]Lu-DPI-4452; [68Ga]Ga-DPI-4452
- Indication: unresectable locally advanced or metastatic solid tumors

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05706129
- Phase: PHASE1, PHASE2
- Status: RECRUITING
- Sponsor: Lumara Bio Oncologics GmbH
- Conditions: Clear Cell Renal Cell Cancer (ccRCC); Pancreatic Ductal Adenocarcinoma (PDAC); Colorectal Cancer (CRC); Urothelial Carcinoma (UC); Indeterminate Renal Mass (IDRM); Muscle Invasive Bladder Cancer (MIBC); Head and Neck Cancer (H&N); Triple Negative Breast Cancer (TNBC); Squamous Non-Small Cell Lung Cancer (NSCLC)
- Interventions: [68Ga]Ga-DPI-4452; [177Lu]Lu-DPI-4452
- Enrollment: 270
- Primary outcome: Part A: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
- Primary outcome: Part B: Number of Participants Experiencing Dose-Limiting Toxicities (DLTs)
- Primary outcome: Part C: Objective Response Rate (ORR)
- Primary outcome: Part D: Concordance Between [68Ga]Ga-DPI-4452 Uptake by PET Imaging and Assessment of Histological Characteristics of IDRM
- Primary outcome: Part E: Radiotracer Uptake at Lesion Level Identified by PET Imaging

## Indexed commentary on NCT05706129 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 2 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct05706129
